LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | Brivanib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4209 | 4223 | 0.9967 | 0.9951 |
SK-BR-3 | Brivanib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4138 | 4223 | 0.9799 | 0.9698 |
SK-BR-3 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4205 | 4223 | 0.9957 | 0.9936 |
BT-20 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3699 | 3769 | 0.9813 | 0.9736 |
MCF 10A | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 962 | 10708 | 10605 | 1.0097 | 1.0107 |
MCF7 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 2423 | 4093 | 0.5922 | 0.4211 |
MCF7 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1209 | 854 | 4093 | 0.2087 | -0.1232 |
MDA-MB-231 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1350 | 4513 | 0.2992 | 0.0349 |
BT-20 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1097 | 732 | 3769 | 0.1942 | -0.1367 |
BT-20 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1097 | 3777 | 3769 | 1.0021 | 1.0029 |
MCF 10A | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 962 | 9430 | 10605 | 0.8893 | 0.8782 |
MDA-MB-231 | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4633 | 4513 | 1.0265 | 1.0365 |
Hs 578T | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 658 | 395 | 3846 | 0.1029 | -0.0823 |
Hs 578T | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 658 | 2458 | 3846 | 0.6392 | 0.5647 |
MDA-MB-231 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4457 | 4513 | 0.9875 | 0.9828 |
Hs 578T | Buparlisib | 0.04 | uM | LJP5 | 72 | hr | 658 | 3642 | 3846 | 0.9470 | 0.9361 |
Hs 578T | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 658 | 1105 | 3846 | 0.2874 | 0.1403 |
MCF 10A | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 962 | 10235 | 10605 | 0.9651 | 0.9616 |
SK-BR-3 | Buparlisib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 2767 | 4223 | 0.6553 | 0.4841 |
MCF7 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 1418 | 4093 | 0.3465 | 0.0724 |
MCF7 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 838 | 4093 | 0.2048 | -0.1287 |
MCF7 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1209 | 977 | 4093 | 0.2389 | -0.0804 |
BT-20 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1097 | 1147 | 3769 | 0.3044 | 0.0187 |
Hs 578T | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 658 | 477 | 3846 | 0.1241 | -0.0567 |
MCF 10A | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 962 | 1383 | 10605 | 0.1304 | 0.0436 |